Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Nutt

Showing results (151-160 of 389) with videos related to

Pageof 39
Sort By:
Drugs & Aging|June 16, 2024
Prescribed Medical Cannabis Use Among Older Individuals: Patient Characteristics and Improvements in Well-Being: Findings from T21Michael T Lynskey, Hannah Thurgur, Alkyoni Athanasiou-Fragkouli, et al.
Journal of Affective Disorders|June 12, 2010
Cytokine levels in euthymic bipolar patientsSinan Guloksuz, Esin Aktas Cetin, Turan Cetin, et al.
Farmaco (Societa Chimica Italiana : 1989)|March 9, 2005
Synthesis of 2,3,5,6-tetrahydro-3H-imidazo[2,1-b] [1,3,5]benzotriazepines and their oxidative ring contraction into 1-(4,5-dihydro-1H-imidazol-2-yl)-1H-benzimidazolesFranciszek Saczewski, Ewa Kobierska, Robin J Tyacke, et al.
Medicinal Research Reviews|June 16, 2011
5-HT radioligands for human brain imaging with PET and SPECTLouise M Paterson, Birgitte R Kornum, David J Nutt, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|March 11, 2009
Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depressionEduard Maron, Anu Tammiste, Kristi Kallassalu, et al.
Neuropharmacology|September 25, 2007
Blockade of alcohol's amnestic activity in humans by an alpha5 subtype benzodiazepine receptor inverse agonistDavid J Nutt, Marie Besson, Susan J Wilson, et al.
Molecular Psychiatry|September 27, 2023
Neuroimaging in psychedelic drug development: past, present, and futureMatthew B Wall, Rebecca Harding, Rayyan Zafar, et al.
Neuroscience and Biobehavioral Reviews|July 31, 2012
GABA system dysfunction in autism and related disorders: from synapse to symptomsSuzanne Coghlan, Jamie Horder, Becky Inkster, et al.
Biological Psychiatry|February 10, 2023
Reply to: No Clear Evidence of Reduced Brain Serotonin Release Capacity in Patients With DepressionEugenii A Rabiner, Claudio Agnorelli, Oliver Howes, et al.
Pharmacology & Therapeutics|May 24, 2022
Cannabinoids and the endocannabinoid system in fibromyalgia: A review of preclinical and clinical researchStephanie L Bourke, Anne Katrin Schlag, Saoirse Elizabeth O'Sullivan, et al.
Pageof 39

Showing results (151-160 of 389) with videos related to

Sort By:
Pageof 39
Drugs & Aging|June 16, 2024
Prescribed Medical Cannabis Use Among Older Individuals: Patient Characteristics and Improvements in Well-Being: Findings from T21Michael T Lynskey, Hannah Thurgur, Alkyoni Athanasiou-Fragkouli, et al.
Journal of Affective Disorders|June 12, 2010
Cytokine levels in euthymic bipolar patientsSinan Guloksuz, Esin Aktas Cetin, Turan Cetin, et al.
Farmaco (Societa Chimica Italiana : 1989)|March 9, 2005
Synthesis of 2,3,5,6-tetrahydro-3H-imidazo[2,1-b] [1,3,5]benzotriazepines and their oxidative ring contraction into 1-(4,5-dihydro-1H-imidazol-2-yl)-1H-benzimidazolesFranciszek Saczewski, Ewa Kobierska, Robin J Tyacke, et al.
Medicinal Research Reviews|June 16, 2011
5-HT radioligands for human brain imaging with PET and SPECTLouise M Paterson, Birgitte R Kornum, David J Nutt, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|March 11, 2009
Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depressionEduard Maron, Anu Tammiste, Kristi Kallassalu, et al.
Neuropharmacology|September 25, 2007
Blockade of alcohol's amnestic activity in humans by an alpha5 subtype benzodiazepine receptor inverse agonistDavid J Nutt, Marie Besson, Susan J Wilson, et al.
Molecular Psychiatry|September 27, 2023
Neuroimaging in psychedelic drug development: past, present, and futureMatthew B Wall, Rebecca Harding, Rayyan Zafar, et al.
Neuroscience and Biobehavioral Reviews|July 31, 2012
GABA system dysfunction in autism and related disorders: from synapse to symptomsSuzanne Coghlan, Jamie Horder, Becky Inkster, et al.
Biological Psychiatry|February 10, 2023
Reply to: No Clear Evidence of Reduced Brain Serotonin Release Capacity in Patients With DepressionEugenii A Rabiner, Claudio Agnorelli, Oliver Howes, et al.
Pharmacology & Therapeutics|May 24, 2022
Cannabinoids and the endocannabinoid system in fibromyalgia: A review of preclinical and clinical researchStephanie L Bourke, Anne Katrin Schlag, Saoirse Elizabeth O'Sullivan, et al.
Pageof 39